First quarter in brief

Decision on new share issue with preferential rights for shareholders taken at Extraordinary General Meeting on March 19, 2018
Patent application for tasquinimod for the treatment of multiple myeloma approved in the US
Product patent for the second patent family in the SILC project granted in the US

Events after the end of the period

The rights issue implemented in April was oversubscribed by approximately 30 percent. The company received a capital infusion of approximately SEK 46,9 M after issue expenses
Our partner NeoTX presented new preclinical data for ANYARA at the AACR Annual Meeting in Chicago

Financial summary

SEK M	Jan-Mar		Full-year
	2018	2017		2017

Net sales	4.8	4.7		20.2
Operating loss	-8.5	-14.6		*-102.5
Loss after tax	-10.2	-15.8		*-108,8
Loss per share (SEK)	-0.11	-0.16		-1.12
Cash and cash equivalents (at close of the period)	12.8	62.7		25.2

* of which write down of property SEK 50 M

For further information, please contact:

Helén Tuvesson, CEO
Tel: +46 (0)46-19 21 56

Hans Kolam, CFO
Tel: +46 (0)46 19 20 44

Active Biotech AB
(Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund
Tel: +46 (0)46-19 20 00

The report is also available at https://www.activebiotech.com/en.

Attachment

Active Biotech AB Interim report January - March 2018